Insight Molecular Diagnostics (NASDAQ: IMDX) furnishes investor presentation via 8-K filing

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. filed a current report to notify investors that it may use a new slide presentation in meetings with investors or analysts. The presentation is attached as Exhibit 99.1 and may be used from time to time to discuss the company and its business.

The company states that this material is being furnished under a disclosure item for Regulation FD and is not considered filed for purposes of liability under the Exchange Act. The presentation will only be incorporated into other SEC filings if explicitly referenced there.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001642380 0001642380 2026-02-11 2026-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 11, 2026

Insight Molecular Diagnostics Inc.

(Exact name of registrant as specified in its charter)

California		1-37648		27-1041563
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

(615) 255-8880

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		IMDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Insight Molecular Diagnostics Inc. (the “Company”) intends, from time to time, to present, utilize, and/or at one or more meetings with investors or analysts a slide presentation, which is attached hereto as Exhibits 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Investor Presentation (furnished herewith pursuant to Item 7.01).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INSIGHT MOLECULAR DIAGNOSTICS INC.
Date: February 11, 2026	By:	/s/ Peter Hong
		Peter Hong
		Vice President, General Counsel

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FAQ

What did Insight Molecular Diagnostics (IMDX) disclose in this 8-K?

Insight Molecular Diagnostics disclosed that it may use an investor slide presentation in meetings with investors or analysts. The presentation is attached as Exhibit 99.1 and is furnished under a disclosure item related to Regulation FD.

What is Exhibit 99.1 in Insight Molecular Diagnostics’ 8-K?

Exhibit 99.1 is an investor presentation that Insight Molecular Diagnostics may present, utilize, or reference at one or more meetings with investors or analysts. It provides supporting materials for discussions but is furnished, not filed, under the current report.

Is the IMDX investor presentation considered filed for Exchange Act liability?

No. Insight Molecular Diagnostics specifies that the investor presentation furnished as Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act. It is instead treated as furnished information under a non-filing disclosure item.

Can the IMDX investor presentation be incorporated into other SEC filings?

The presentation will only be incorporated into other SEC filings if expressly stated. Insight Molecular Diagnostics notes that Exhibit 99.1 is not automatically incorporated by reference into Exchange Act or Securities Act filings unless specifically referenced there.

Why did Insight Molecular Diagnostics use Item 7.01 for this 8-K?

Insight Molecular Diagnostics used a disclosure item corresponding to Regulation FD to furnish its investor presentation. This allows the company to share information it may discuss with investors or analysts without treating the material as filed for liability purposes.

Filing Exhibits & Attachments

40 documents

Press Releases

• EX-99.1 EX-99.1 29.9 KB
• EX-99 GRAPHIC 257.1 KB
• EX-99 GRAPHIC 777.8 KB
• EX-99 GRAPHIC 282.5 KB
• EX-99 GRAPHIC 341.8 KB
• EX-99 GRAPHIC 352.0 KB
• EX-99 GRAPHIC 240.7 KB
• EX-99 GRAPHIC 238.5 KB
• EX-99 GRAPHIC 268.1 KB
• EX-99 GRAPHIC 260.0 KB
• EX-99 GRAPHIC 289.8 KB
• EX-99 GRAPHIC 328.7 KB
• EX-99 GRAPHIC 420.8 KB
• EX-99 GRAPHIC 315.6 KB
• EX-99 GRAPHIC 429.1 KB
• EX-99 GRAPHIC 228.0 KB
• EX-99 GRAPHIC 359.6 KB
• EX-99 GRAPHIC 306.3 KB
• EX-99 GRAPHIC 471.6 KB
• EX-99 GRAPHIC 315.2 KB
• EX-99 GRAPHIC 432.5 KB
• EX-99 GRAPHIC 619.6 KB
• EX-99 GRAPHIC 475.7 KB
• EX-99 GRAPHIC 979.8 KB
• EX-99 GRAPHIC 337.3 KB
• EX-99 GRAPHIC 318.2 KB
• EX-99 GRAPHIC 405.4 KB
• EX-99 GRAPHIC 182.1 KB
• EX-99 GRAPHIC 434.6 KB
• EX-99 GRAPHIC 360.8 KB
• EX-99 GRAPHIC 304.4 KB
• EX-99 GRAPHIC 378.6 KB
• EX-99 GRAPHIC 568.4 KB
• EX-99 GRAPHIC 246.0 KB
• EX-99 GRAPHIC 296.2 KB
• EX-99 GRAPHIC 646.4 KB
• EX-99 GRAPHIC 173.9 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB